Clinical Trials
SLEIPNIR Platform Trial Advances with Mirivadelgat Addition
The SLEIPNIR Phase 2a platform trial — led by Professor Charalampos Tzoulis at Haukeland University Hospital in Bergen, Norway — has selected mirivadelgat, an oral ALDH2 activator from Foresee Pharmaceuticals, to enter clinical testing. The drug works by activating ALDH2 to break down toxic aldehyde byproducts that accumulate in Parkinson's patients' brains, potentially slowing disease progression. Five days ago (June 8, 2026), Foresee announced the collaboration, marking another candidate entering this innovative multi-arm platform designed to test multiple drugs simultaneously against a single placebo group, accelerating the path to identifying effective treatments. *
parkinsonsnewstoday.comPrasinezumab Sustains Motor Progression Benefits in PASADENA Open-Label Extension
The PASADENA trial's open-label extension continues to show that prasinezumab (RO7046015/PRX002) — a monoclonal antibody targeting aggregated α-synuclein — produces a sustained effect on Parkinson's disease motor progression in early-stage participants. Participants who continued or switched to prasinezumab maintained slower motor decline compared to historical baselines. A separate Phase III trial (NCT03100149) is now actively recruiting to confirm these findings in a larger population. The Michael J. Fox Foundation calls prasinezumab "at the leading edge of treatments aiming to target disease biology believed to underlie the brain cell degeneration seen in Parkinson's disease." *
michaeljfox.orgBIIB122 LRRK2 Inhibitor Trial Discontinued After Phase IIb Failure
Biogen and Denali Therapeutics announced in early June 2026 that they are discontinue development of BIIB122 (DNL151), an LRRK2 inhibitor that had been in a Phase IIb trial called LUMA for early-stage idiopathic Parkinson's disease. The trial failed to meet its efficacy endpoint, dealing a setback to the genetically-informed disease-modification strategy targeting LRRK2 mutations. While the approach was scientifically sound, it did not translate into clinical benefit in this patient population — a reminder that promising preclinical and genetic targets don't always survive in human trials. *
finance.yahoo.com
Breakthrough Treatments
Japan Grants Conditional Approval for Amchepry, World's First iPSC Parkinson's Therapy
In March 2026, Japan became the first country in the world to conditionally approve Amchepry — a stem cell therapy for Parkinson's disease involving the transplantation of dopamine neurons derived from induced pluripotent stem cells (iPSCs). The treatment is designed for patients who are unresponsive to levodopa and aims to replace dopamine-producing brain cells. Early trials showed increased dopamine levels and motor improvements with mostly mild side effects. A separate U.S. clinical trial is underway using DSP-1083, a similar iPSC-derived dopaminergic neural progenitor cell product from Sumitomo Pharma America. This landmark approval paves the way for regenerative approaches to move from laboratory into clinical practice. *
parkinsonsnewstoday.comMJFF Awards $195M+ in Early 2026 Research Grants
The Michael J. Fox Foundation announced over $195 million in awarded grants during early 2026, spanning treatment development, precision medicine, genetics, and disease biology. The largest-ever funding commitment from the foundation signals aggressive forward momentum toward disease-modifying therapies ahead of the National Plan to End Parkinson's Act implementation. The foundation continues to fund trials targeting α-synuclein, LRRK2, and emerging pathways like ALDH2 activation. *
Lifestyle Interventions
PRIME Study Launches: Mediterranean Diet + Exercise for Parkinson's Gut Health
A new multicenter, randomized controlled pilot study called PRIME (Effects of combined Mediterranean diet and physical activity intervention on the gut microbiome and disease progression in individuals with Parkinson's disease) has been launched to investigate whether combining a Mediterranean diet with physical activity can slow Parkinson's disease progression through gut microbiome changes. The study is published in Frontiers in Aging Neuroscience (2026) and represents a growing body of research recognizing the gut-brain axis in Parkinson's. This builds on established evidence that both exercise and Mediterranean-style eating independently benefit Parkinson's symptoms, and now tests whether together they produce additive or synergistic effects. *
frontiersin.orgNutrition-Sleep Connection in Parkinson's: New Study Highlights Clinical Importance
A study from Peking University published in Frontiers in Neurology (January 2026) investigated the relationship between nutritional status and sleep quality in Parkinson's disease patients. The research found that malnutrition and sleep disturbances are both prevalent in PD and are closely linked — poor nutrition correlates with worse sleep quality, and sleep problems in turn can worsen nutritional status. The findings underscore the importance of addressing sleep as part of comprehensive Parkinson's care, not just as a nuisance symptom but as a factor that directly affects overall disease management and quality of life. *
frontiersin.org
Emerging Research
Scientists Identify Brain Network Driver of Parkinson's Disease Progression
An international study published in February 2026 identified a specific brain network — the SCAN (salience, cingulate, auditory, and default mode network connections) — as a core driver of Parkinson's disease progression. Researchers found that this network becomes abnormally over-connected in PD patients, disrupting not just motor control but also cognition and autonomic function. The analysis showed excessive connectivity between the SCAN network and the subcortex, a brain region involved in emotion, memory, and motor control. This network-level understanding could open entirely new therapeutic targets beyond dopamine replacement, potentially leading to treatments that address non-motor symptoms like depression and cognitive decline that often trouble PD patients more than motor symptoms. *
sciencedaily.comFAM171A2 Identified as Neuronal Receptor for α-Synuclein Fibrils
A study published in Science (2026) identified the product of the PD-risk gene FAM171A2 as the neuronal receptor responsible for the uptake of α-synuclein fibrils into brain cells. This discovery explains a key step in how pathological α-synuclein spreads through the brain in Parkinson's disease — from cell to cell, propagating the protein aggregates that characterize the disease. Understanding this receptor opens a potential therapeutic avenue: blocking FAM171A2 could prevent the spread of α-synuclein pathology, potentially slowing or halting disease progression at a fundamental biological level. *
science.orgGPNMB Confirmed as PD Risk Gene Through α-Synuclein Interaction
Research published in Science has established GPNMB (glycoprotein non-metastatic melanoma protein B) as a genuine Parkinson's disease risk gene through its direct interaction with α-synuclein. Computational, cell biological, and human tissue-based studies confirm that GPNMB confers Parkinson's risk by physically interacting with α-synuclein, making it both a risk marker and a potential therapeutic target. This adds to the growing list of genes — including LRRK2, GBA, and SNCA — that illuminate the molecular pathways underlying Parkinson's and provide handles for drug development. *
science.org
This report is for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.